CTOs on the Move


 
  • Number of Employees:
  • Annual Revenue:

  • ,

Executives

Name Title Contact Details

Similar Companies

BIA GROUP

Since 1902, BIA is recognized by its customers for the quality of its products and services in the mining and quarrying, construction, transport and energy sectors as exclusive distributor of Komatsu equipment and parts, as well as other reputable manufacturers like Metso, Cummins, Bomag, MAN, Foton, Furukawa, GHH… for complementary products.​ Today BIA Group has become a well-established, multinational and trusted long-term business partner, operating in more than 20 countries in Africa and in the Benelux regions. The family-owned group distinguishes itself through the extent of its network and state-of-the-art technical facilities to support its clients close to their operations.​ The group is continuously developing its capabilities and expertise to meet the ever-growing customer needs. BIA provides a wide range of solutions including equipment sales, rental, parts supply, aftersales services as well as support services such as structured financing solutions, supply chain management and training to assist its customers on their projects development. More recently, BIA was pioneer in adopting innovation & technology solutions to increase customers productivity and safety on sites.

Ensemble Performing Arts

Ensemble Performing Arts is a partnership of community-focused music and dance businesses that maintain individual identities while sharing resources to ensure their mutual success. We believe that a performing arts education is a lifelong journey and is appropriate for individuals of all ages and skill levels. While many of our teachers are equipped to serve students with collegiate and professional ambitions, and we celebrate our students with these meritorious goals, we are equally delighted to work with students of all abilities seeking to enrich their lives through the performing arts. Students can expect a fun and welcoming learning environment with quality teachers underpinned by individual assessments and personalized guidance throughout their learning journey. While our focus always begins with safe classroom practices and healthy technique, what follows thereafter depends on a students unique interests, abilities, and ambitions. We celebrate differences in both teaching styles and learning styles, and always work to find a good fit for our students among our faculty and programs.

Athol Savings Bank

Athol Savings Bank is a mutual savings bank based in Athol, Massachusetts. Our goal is to be the financial foundation in our community; working harder, reaching higher, and delivering strength, stability, and security to our customers. As we move forward, Athol Savings Bank is committed to being "A Solutions Bank" for our customers and the communities we serve. Member FDIC. Equal Housing Lender. Member DIF.

IMUNON

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.